

CLAIMS

1. A recombinant modified vaccinia virus Ankara (MVA) comprising at least one nucleotide sequence encoding an antigenic determinant of a respiratory syncytial virus (RSV) membrane glycoprotein F encoding at least one of the amino acid sequences of SEQ ID NO:4, 6 and 16 and at least one nucleotide sequence encoding the amino acid sequence of SEQ ID NO:18, SEQ ID NO:33 and SEQ ID NO:10.
2. A recombinant modified vaccinia virus Ankara (MVA) of claim 1, wherein the at least one nucleotide sequence encoding an antigenic determinant of the respiratory syncytial virus (RSV) membrane glycoprotein F comprises the nucleotide sequence of SEQ ID NO:5.
3. The recombinant MVA of claims 1 - 2, wherein the nucleotide sequence encoding the amino acid sequence of SEQ ID NO:18 comprises the nucleotide sequence of SEQ ID NO:17.
4. The recombinant MVA of claims 1 ~~to~~ - 3 further comprising at least one nucleotide sequence encoding an antigenic determinant of an RSV G membrane glycoprotein.
5. The recombinant MVA of claim 4, wherein the nucleotide sequence encoding an antigenic determinant of the RSV G membrane glycoprotein is derived from RSV strain A, preferably from strain A2, and/or B.
6. The recombinant MVA of claims ~~s~~ 4 ~~or~~ - 5, wherein the nucleotide sequence encoding an antigenic determinant of the RSV G membrane glycoprotein comprises a nucleotide sequence encoding the amino acid sequence selected from SEQ ID NO:2 ~~or~~ and 8.
7. The recombinant MVA of claims 4 ~~or~~ - 5, wherein the nucleotide sequence encoding an antigenic determinant of the RSV G membrane glycoprotein comprises the nucleotide sequence selected from SEQ ID NO:1 ~~or~~ and 7.
8. The recombinant MVA of claims 4 ~~to~~ - 5, further comprising an antigenic determinant of a second RSV G membrane glycoprotein.
9. The recombinant MVA of claims 1 ~~to~~ - 8, comprising a nucleotide sequence encoding an antigenic determinant comprising SEQ ID NO:1 and 7 or encoding the amino acid sequence of SEQ ID NO: 2 and 8.
10. A pharmaceutical composition and/or vaccine comprising the recombinant MVA of claims 1 ~~to~~ - 9 and, optionally, a pharmaceutically acceptable carrier and/or diluent.

11. The use of a recombinant MVA of claims s 1 to 9 for the manufacture of a medicament for treating or preventing RSV infection.
12. The use of a recombinant modified vaccinia virus Ankara (MVA) of claims 1 to 9 for the manufacture of a medicament for treating or preventing an RSV infection by intranasal administration ~~and/or subcutaneous application~~.
13. The use of a recombinant modified vaccinia virus Ankara (MVA) of claims s 1 to 9 for the manufacture of a medicament for treating or preventing an RSV infection by subcutaneous application ~~intranasal administration~~.
- ~~14. The use of a recombinant modified vaccinia virus Ankara (MVA) of claims 1 to 9 for the manufacture of a medicament for treating or preventing an RSV infection by intranasal administration, wherein an intramuscular administration is excluded.~~
- ~~15.~~ 14. The use of the recombinant MVA of claims s 11 to 14 ~~13~~ or the use of the pharmaceutical composition and/or vaccine of claims 10, wherein the recombinant MVA or the pharmaceutical composition and/or vaccine is or is to be administered in a single dose or in multiple doses ~~to an~~ in an immunologically naïve ~~or an immunologically experienced~~ human subject.
- ~~16.~~ 15. The use of the recombinant MVA of claim ~~14~~ 12 ~~comprising~~ solely by intranasal administration.
- ~~17.~~ 16. The use of the recombinant MVA of ~~any one of~~ claims 11 ~~to 16~~ 15 ~~or the use of the pharmaceutical composition and/or vaccine of claim 10, wherein the recombinant MVA or the pharmaceutical composition and/or vaccine is administered to~~ in a human subject with more than 2 years of age.
- ~~18.~~ 17. The use of the recombinant MVA of ~~any one of~~ claims 11 ~~to 16~~ 15 ~~or the use of the pharmaceutical composition and/or vaccine of claim 10, wherein the recombinant MVA or the pharmaceutical composition and/or vaccine is administered to~~ in a human subject ~~with less than~~ under 2 years of age.
- ~~19.~~ 18. The recombinant MVA of ~~any of~~ claims 1 to 9, wherein the MVA used for generating the recombinant MVA is MVA-BN or a derivative thereof.